Search

Your search keyword '"Marolleau, J P"' showing total 270 results
Start Over Author "Marolleau, J P"
270 results on '"Marolleau, J P"'

2. Molecular and clinical diversity in primary central nervous system lymphoma

Author

Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., and Alentorn, A.

Published
2023
Full Text
View/download PDF

5. Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma.

Author

Marchal, E., Palard-Novello, X., Lhomme, F., Meyer, M. E., Manson, G., Devillers, A., Marolleau, J. P., Houot, R., and Girard, A.

Subjects
B cells, B cell lymphoma, T cells, OVERALL survival, CYTOKINE release syndrome, BODY surface area
Abstract

Purpose: Chimeric antigen receptor (CAR) T cells have established themselves as an effective treatment for refractory or relapsed large B cell lymphoma (LBCL). Recently, the sDmax, which corresponds to the distance separating the two farthest lesions standardized by the patient's body surface area, has appeared as a prognostic factor in LBCL. This study aimed to identify [18F]FDG-PET biomarkers associated with prognosis and predictive of adverse events in patients treated with CAR T cells. Methods: Patients were retrospectively included from two different university hospitals. They were being treated with CAR T cells for LBCL and underwent [18F]FDG-PET just before CAR T cell infusion. Lesions were segmented semi-automatically with a threshold of 41% of the maximal uptake. In addition to clinico-biological features, sDmax, total metabolic tumor volume (TMTV), SUVmax, and uptake intensity of healthy lymphoid organs and liver were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The occurrence of adverse events, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), was reported. Results: Fifty-six patients were included. The median follow-up was 9.7 months. Multivariate analysis showed that TMTV (cut-off of 36 mL) was an independent prognostic factor for PFS (p < 0.001) and that sDmax (cut-off of 0.15 m−1) was an independent prognostic factor for OS (p = 0.008). Concerning the occurrence of adverse events, a C-reactive protein level > 35 mg/L (p = 0.006) and a liver SUVmean > 2.5 (p = 0.027) before CAR T cells were associated with grade 2 to 4 CRS and a spleen SUVmean > 1.9 with grade 2 to 4 ICANS. Conclusion: TMTV and sDmax had independent prognostic values, respectively, on PFS and OS. Regarding adverse events, the mean liver and spleen uptakes were associated with the occurrence of grade 2 to 4 CRS and ICANS, respectively. Integrating these biomarkers into the clinical workflow could be useful for early adaptation of patients management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study

Author

Schorb, E, Fox, C P, Fritsch, K, Isbell, L, Neubauer, A, Tzalavras, A, Witherall, R, Choquet, S, Kuittinen, O, De-Silva, D, Cwynarski, K, Houillier, C, Hoang-Xuan, K, Touitou, V, Cassoux, N, Marolleau, J-P, Tamburini, J, Houot, R, Delwail, V, Illerhaus, G, Soussain, C, and Kasenda, B

Published
2017
Full Text
View/download PDF

8. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL

Author

Zinzani, P. L., primary, Ansell, S. M., additional, Bosch, F., additional, Friedberg, J. W., additional, Marolleau, J. P., additional, Arcaini, L., additional, Garcia-Sanz, R., additional, Gopal, A. K., additional, Grande, C., additional, Merryman, R., additional, Pinto, A., additional, Smith, S. D., additional, Villasboas, J. C., additional, Wallace, D., additional, Fagerberg, J., additional, Magalhaes, J. G., additional, and Armand, P., additional

Published
2022
Full Text
View/download PDF

9. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

Author

Schavgoulidze, A., primary, Perrot, A., additional, Cazaubiel, T., additional, Leleu, X., additional, Manier, S., additional, Buisson, L., additional, Maheo, S., additional, Do Souto Ferreira, L., additional, Lannes, R., additional, Pavageau, L., additional, Hulin, C., additional, Marolleau, J.-P., additional, Voillat, L., additional, Belhadj, K., additional, Divoux, M., additional, Slama, B., additional, Brechignac, S., additional, Macro, M., additional, Stoppa, A.-M., additional, Sanhes, L., additional, Orsini-Piocelle, F., additional, Fontan, J., additional, Chretien, M.-L., additional, Demarquette, H., additional, Mohty, M., additional, Avet-Loiseau, H., additional, and Corre, J., additional

Published
2022
Full Text
View/download PDF

12. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Author

Largeaud, Laetitia, Cornillet-Lefebvre, Pascale, Hamel, Jean-François, Dumas, Pierre-Yves, Prade, Naïs, Dufrechou, Stéphanie, Plenecassagnes, Julien, Luquet, Isabelle, Blanchet, Odile, Banos, Anne, Béné, Marie, Bernard, Marc, Bertoli, Sarah, Bonmati, Caroline, Fornecker, Luc Matthieu, Guièze, Romain, Haddaoui, Lamya, Hunault, Mathilde, Ianotto, Jean Christophe, Jourdan, Eric, Ojeda, Mario, Peterlin, Pierre, Vey, Norbert, Zerazhi, Hacene, Yosr, Hicheri, Mineur, Ariane, Cahn, Jean-Yves, Ifrah, Norbert, Récher, Christian, Pigneux, Arnaud, Delabesse, Eric, Marolleau, J.-P., Aleme, A., Orsini-Piocelle, F., Cadoux, N., Marie, C., Al Jijakli, A., Lepeu, G., Beyrne, M., Labarrere, S., Deconinck, E., Peria, M., El Yamani, A., Kadiri, O., Choufi, B., Brument, M., Leguay, T., Berthou, C., Guillerm, G., Drugmanne, G., Tournilhac, O., Roy, G., Audhuy, B., Camara, S., Caillot, D., Grandjean, M., Bulabois, C.-E., Fief, B., Ladraa, C., Dorvaux, V., Hagopian, M., Fegueux, N., Fenoll, C., Sabadash, V., Haby, C., Witz, F., Lhuire, M., Delaunay, J., Airiau, L., Mannone, L., Touitou, I., Umuhire, D., Alexis, M., Michel, O., Dreyfus, F., Bouscary, D., Cheung, A., Sanhes, L., Touhami, F., Ribas, E., Puyade, M., Gallego-Hernanz, M.-P., Hugon, N., Himberlin, C., Maggi, L., Lamy, T., Testu, A., Tavernier, E., Marchand, S., Lioure, B., Kravanja, C., Benboubker, L., Nollet, D., Attal, M., Sarry, A., Lhermitte, A., Yrica, G., Schwartz, D., Le Montagner, N., Auvray, L., Delepine, R., Fayault, A., Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Hématologie Biologique [Hôpital Robert Debré, Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire, F-33000 Bordeaux, France., Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de la Côte Basque (CHCB), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Hématologie Clinique (BREST - Hémato Clinique), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, NPM1, Karyotype, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk profile, law.invention, 03 medical and health sciences, Cytogenetics, 0302 clinical medicine, Randomized controlled trial, law, Lomustine, Internal medicine, medicine, Biomarkers, Tumor, Idarubicin, Humans, Antineoplastic Agents, Alkylating, ComputingMilieux_MISCELLANEOUS, Chromosome Aberrations, business.industry, Cytarabine, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, Prognosis, 3. Good health, Leukemia, Myeloid, Acute, 030104 developmental biology, 030220 oncology & carcinogenesis, Karyotyping, Mutation, Female, business, Nucleophosmin, medicine.drug
Abstract

International audience; We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine, identified 1088 mutations with an average of 3.3 mutations per patient. NPM1, FLT3, and DNMT3A were the most frequently mutated genes. A putative therapeutic target was identified in 178 patients (54%). Among five molecular classifications analyzed, the ELN2017 risk classification has the stronger association with the clinical evolution. Patients not treated with lomustine have an expected survival prognosis in agreement with this classification regarding the overall and event-free survivals. In strong contrast, lomustine erased the ELN2017 classification prognosis. The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.

Published
2021
Full Text
View/download PDF

15. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease

Author

Jardin, F, Callanan, M, Penther, D, Ruminy, P, Troussard, X, Kerckaert, J P, Figeac, M, Parmentier, F, Rainville, V, Vaida, I, Bertrand, P, Duval, A B, Picquenot, J M, Chaperot, L, Marolleau, J P, Plumas, J, Tilly, H, and Bastard, C

Published
2009
Full Text
View/download PDF

16. Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer

Author

Payrard-Starck, C., Fourcade, A., An Nguyen, T., Tissot, V., Doucet, L., Marolleau, J., Lucas, C., Fournier, G., and Valeri, A.

Abstract

To compare the correlation of Gleason score (GS) and ISUP grade determined by prostate biopsies (PBx) and radical prostatectomy (RP) specimens according to the biopsy technique: ultrasound randomised (RBx) vs. MRI/ultrasound fusion targeted (TBx).

Published
2023
Full Text
View/download PDF

31. S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Author

Moreau, P., primary, Attal, M., additional, Hulin, C., additional, Arnulf, B., additional, Belhadj, K., additional, Benboubker, L., additional, Béné, M. C., additional, Broijl, A., additional, Caillon, H., additional, Caillot, D., additional, Corre, J., additional, Delforge, M., additional, Dejoie, T., additional, Doyen, C., additional, Facon, T., additional, Sonntag, C., additional, Garderet, L., additional, Jie, K.-S., additional, Karlin, L., additional, Kuhnowski, F., additional, Lambert, J., additional, Leleu, X., additional, Lenain, P., additional, Macro, M., additional, Orsini-Piocelle, F., additional, Perrot, A., additional, Stoppa, A.-M., additional, van de Donk, N. W., additional, Wuilleme, S., additional, Zweegman, S., additional, Kolb, B., additional, Touzeau, C., additional, Roussel, M., additional, Tiab, M., additional, Marolleau, J.-P., additional, Meuleman, N., additional, Vekemans, M.-C., additional, Westerman, M., additional, Klein, S. K., additional, Levin, M.-D., additional, Escoffre-Barbe, M., additional, Eveillard, J.-R., additional, Garidi, R., additional, Ahmadi, T., additional, Zhuang, S., additional, Chiu, C., additional, Pei, L., additional, Vanquickelberghe, V., additional, de Boer, C., additional, Smith, E., additional, Deraedt, W., additional, Kampfenkel, T., additional, Schecter, J., additional, Vermeulen, J., additional, Avet-Loiseau, H., additional, and Sonneveld, P., additional

Published
2019
Full Text
View/download PDF

32. Erratum: Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease

Author

Jardin, F, Callanan, M, Penther, D, Ruminy, P, Troussard, X, Kerckaert, J P, Figeac, M, Parmentier, F, Rainville, V, Vaida, I, Bertrand, P, Duval, A B, Picquenot, J M, Chaperot, L, Marolleau, J P, Plumas, J, Tilly, H, and Bastard, C

Published
2009
Full Text
View/download PDF

40. First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma

Author

Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., Amorim, S., Ramadan, S., Bras, F. L., Erlanson, Martin, Herbaux, C., Marolleau, J-P, Nicolas-Virelezier, E., Casasnovas, O., Stamatoullas-Bastard, A., Ferme, C., Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., Amorim, S., Ramadan, S., Bras, F. L., Erlanson, Martin, Herbaux, C., Marolleau, J-P, Nicolas-Virelezier, E., Casasnovas, O., Stamatoullas-Bastard, A., and Ferme, C.

Published
2017
Full Text
View/download PDF

41. STEM CELL COLLECTION AFTER FAILURE OF UPFRONT ABVD OR BEACOPP IN PATIENTS WITH HIGH RISK ADVANCED STAGE III-IV HODGKIN'S LYMPHOMA

Author

Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., Amorim, S., Ramadan, S., Le Bras, F., Erlanson, Martin, Herbaux, C., Marolleau, J. P., Nicolas-Virelizier, E., Casasnovas, O., Stamatoullas-Bastard, A., Ferme, C., Ghez, D., Fortpied, C., Mounier, N., Carde, P., Perrot, A., Khaled, H., Amorim, S., Ramadan, S., Le Bras, F., Erlanson, Martin, Herbaux, C., Marolleau, J. P., Nicolas-Virelizier, E., Casasnovas, O., Stamatoullas-Bastard, A., and Ferme, C.

Abstract

Supplement: 5, Meeting Abstract: P091

Published
2016

45. Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin’s Primary Bone Lymphoma

Author

Schmidt-Tanguy, A., primary, Houot, R., additional, Lissandre, S., additional, Abgrall, J. F., additional, Casassus, P., additional, Rodon, P., additional, Desablens, B., additional, Marolleau, J. P., additional, Garidi, R., additional, Lamy, T., additional, Moles-Moreau, M.-P., additional, and Damaj, G., additional

Published
2014
Full Text
View/download PDF

50. Intensification thérapeutique dans les maladies auto-immunes

Author

Mahevas, M., primary, Vaida, I., additional, Le Page, L., additional, Sid-Idris, S., additional, Royer, B., additional, Garedi, R., additional, Damaj, G., additional, Duhaut, P., additional, Claisse, J.-F., additional, Ducroix, J.-P., additional, and Marolleau, J.-P., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results